News Uzedy extended-release injectable approved by FDA for treatment of Schizophrenia April 28, 2023 Read More » FDA Approves Abilify Asimtufii® (aripiprazole) for the Treatment of Schizophrenia or Maintenance Monotherapy Treatment of Bipolar I Disorder in Adults April 28, 2023 Read More » Teva Initiates Voluntary Nationwide Recall of Specific Lots of Fentanyl Buccal Tablets CII Due to a Labeling Error April 27, 2023 Read More » Akorn Issues Voluntary Nationwide Recall of Various Human and Animal Drug Products Within Expiry Due to Company Shutdown April 26, 2023 Read More » Vowst April 26, 2023 Read More » Qalsody April 25, 2023 Read More » FDA clarifies pharmacist recommendations in Buprenorphine for Opioid Dependence REMS April 19, 2023 Read More » Novartis Announces Positive Topline Results for Kisquali as Adjuvant Treatment for Early Breast Cancer April 19, 2023 Read More » FDA Adds Quinacrine Hydrochloride (quinacrine) to the List of Bulk Drug Substances that May Be Used in Compounding by Outsourcing Facilities (503B Bulks List) April 19, 2023 Read More » Page1 … Page16 Page17 Page18 Page19 Page20 … Page45 Benefit Advisors & Employees - Want to know more? Members: Please call the number on the back of your ID card or e-mail member.services@benecardpbf.com Clients: Contact your Client Relations Manager Full Name(Required) Email(Required) Comment(Required) Company Name(Required) CAPTCHA
Uzedy extended-release injectable approved by FDA for treatment of Schizophrenia April 28, 2023 Read More »
FDA Approves Abilify Asimtufii® (aripiprazole) for the Treatment of Schizophrenia or Maintenance Monotherapy Treatment of Bipolar I Disorder in Adults April 28, 2023 Read More »
Teva Initiates Voluntary Nationwide Recall of Specific Lots of Fentanyl Buccal Tablets CII Due to a Labeling Error April 27, 2023 Read More »
Akorn Issues Voluntary Nationwide Recall of Various Human and Animal Drug Products Within Expiry Due to Company Shutdown April 26, 2023 Read More »
FDA clarifies pharmacist recommendations in Buprenorphine for Opioid Dependence REMS April 19, 2023 Read More »
Novartis Announces Positive Topline Results for Kisquali as Adjuvant Treatment for Early Breast Cancer April 19, 2023 Read More »
FDA Adds Quinacrine Hydrochloride (quinacrine) to the List of Bulk Drug Substances that May Be Used in Compounding by Outsourcing Facilities (503B Bulks List) April 19, 2023 Read More »